The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation
Yonsei Medical Journal
;
: 1638-1642, 2015.
Artículo
en Inglés
| WPRIM
| ID: wpr-70408
ABSTRACT
PURPOSE:
Recently, bortezomib has been used to treat antibody-mediated rejection (AMR) refractory to conventional treatment such as plasmapheresis, intravenous immunoglobulin, and rituximab. The authors aimed to describe their experiences when bortezomib was used to treat refractory AMR. MATERIALS ANDMETHODS:
Eleven refractory AMR episodes treated with bortezomib were included in this study. The patients received one or two cycles of bortezomib (1.3 mg/m2) on days 1, 4, 8, and 11.RESULTS:
Bortezomib effectively reduced antibodies against various targets, including human leukocyte antigen (HLA) class I and II, ABO blood group antigen, and angiotensin II type 1 receptor. Antibodies were depleted or reduced significantly in eight AMR episodes. Overall, there was a significant improvement in the mean estimated glomerular filtration rate (eGFR) at 3 months after therapy (36.91+/-22.15 mL/min/1.73 m2) versus eGFR at time of AMR diagnosis (17.00+/-9.25 mL/min/1.73 m2; p=0.007). All six early-onset AMR episodes (within 6 months post-transplantation) showed full recovery of allograft function. Additionally, three of the five late-onset AMR episodes (>6 months post-transplantation) showed improved allograft function.CONCLUSION:
Anti-humoral treatment based on bortezomib might be an effective strategy against refractory AMR caused by various types of antibodies. Notably, this treatment could be more effective in early-onset AMR than in late-onset AMR.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Pirazinas
/
Trasplante Homólogo
/
Ácidos Borónicos
/
Trasplante de Riñón
/
Plasmaféresis
/
Inmunoglobulinas Intravenosas
/
Bortezomib
/
Rechazo de Injerto
/
Factores Inmunológicos
/
Isoanticuerpos
Límite:
Adolescente
/
Adulto
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Yonsei Medical Journal
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS